Afamitresgene Autoleucel

Summary

Afamitresgene Autoleucel (CHEMBL4802254) is an approved gene; indicated across 2 conditions including synovial sarcoma and neoplasm; with CIViC clinical evidence for 1 variant-indication association (e.g. MAGEA4 Expression AND ( HLA-A *02:01P OR HLA-A *02:02P OR HLA-A *02:03P OR HLA-A *02:06P ) in synovial sarcoma).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Gene
• Indications: 2 conditions
• Clinical trials: 1
• Precision-oncology evidence (CIViC): 1 variant–indication association

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4802254
Name	Afamitresgene Autoleucel
Type	Gene
Max phase	4

Also known as: Afamitresgene autoleucel, MAGE-A4c1032T, Tecelra, AFAMITRESGENE AUTOLEUCEL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
synovial sarcoma	4	MONDO:0010434	EFO:0001376
neoplasm	1	MONDO:0005070	EFO:0000616

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05642455	PHASE1/PHASE2	RECRUITING	SPEARHEAD-3 Pediatric Study

Clinical evidence (CIViC)

Variant × indication × effect (1 predictive associations from 1 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
MAGEA4 Expression AND ( HLA-A *02:01P OR HLA-A *02:02P OR HLA-A *02:03P OR HLA-A *02:06P )	Synovial Sarcoma	Sensitivity/Response	Afamitresgene Autoleucel	CIViC A	EID12138

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).